Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
McKesson

Last Updated: December 10, 2019

DrugPatentWatch Database Preview

Litigation Details for ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC (D.N.J. 2007)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC (D.N.J. 2007)

Docket   Start Trial Date Filed 2007-08-09
Court District Court, D. New Jersey Date Terminated 2010-08-25
Cause 35:183 Patent Infringement Assigned To Dennis M. Cavanaugh
Jury Demand Defendant Referred To Magistrate Judge Joseph A. Dic
Parties ACTAVIS ELIZABETH LLC; APOTEX CORP.; APOTEX, INC.; AUROBINDO; CHAMBERLAIN COMMUNICATIONS GROUP, LLC; ELI LILLY AND COMPANY; GLENMARK PHARMACEUTICALS INC., USA; MYLAN PHARMACEUTICALS INC.; SANDOZ INC.; SUN PHARMACEUTICALS; SYNTHON LABORATORIES, INC.; TEVA PHARMACEUTICALS; ZYDUS PHARMACEUTICALS USA INC.
Patents 10,183,005; 4,018,895; 4,194,009; 4,314,081; 4,626,549; 4,663,318; 5,631,021; 5,658,590; 6,297,014; 6,326,018; 6,433,003; 7,078,020; 7,417,022; 8,217,012; 8,399,015; 8,445,018; 8,624,003; 9,081,016; 9,297,018; 9,399,025; 9,574,010; 9,616,024
Attorneys ARNOLD B. CALMANN; ARTHUR L. LESSLER; BRIAN JEFFREY ROBINSON; CHRISTOPHER G. FITZPATRICK; DAVID J. COONER; ERIC I. ABRAHAM; FRANK HOLAHAN; GREGORY D. MILLER; JAMES E. CECCHI; JAMES S. FRIEDMAN; JAMES S. RICHTER; JANE JHUN; JEFFREY S. SOOS; JOHN C. GARDE; JOHN F. BRENNER; JOSEPH NICHOLAS FROEHLICH; KATHERINE ANN ESCANLAR; KEVIN MICHAEL RYAN; MAYRA VELEZ TARANTINO; MELISSA ANNE CHUDEREWICZ; MELISSA E. FLAX; MELISSA STEEDLE BOGAD; MICHAEL ANDREW HOLTMAN; MICHAEL E. PATUNAS; PAUL L. KATTAS; STEVEN J. LEE; VICTORIA ELIZABETH SPATARO
Firms Alston & Bird LLP; Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C.; Carella, Byrne, Cecchi, Olstein, Brody & Agnello, PC; Eric I. Abraham; Finnegan Henderson Farabow Garrett and Dunner; Goodwin Procter LLP, the New York Times Building; Kelley Drye Warren, LLP; Kenyon & Kenyon LLP; Lessler & Lessler; McCarter & English, LLP; McElroy, Deutsch, Mulvaney & Carpenter, LLC; Pepper Hamilton LLP; Reppert Kelley; Saiber, LLC; Smith, Gambrell & Russell, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC

Details for ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC (D.N.J. 2007)

Date Filed Document No. Description Snippet Link To Document
2008-07-15 190 infringement of U.S. Pat. No. 5,658,590 (“the ‘590 patent”). The ‘590 patent covers a method of using the… will not have patent prosecution responsibilities for current or future Lilly patent applications concerning… BACKGROUND Eli Lilly brought this patent infringement action against defendants alleging…preparation or prosecution of any patent application that covers tomoxetine or atomoxetine…plaintiff’s in-house counsel from prosecuting patent applications for the duration of this action and External link to document
2009-05-21 331 of treatment patent. On August 19, 1997, U.S. Patent No. 5,658,590 (the “‘590 Patent”), titled “Treatment…atomoxetine before the ‘590 Patent expires. Lilly initiated this action for patent infringement under 35 U.S.C…expiration of the ‘590 Patent would constitute further infringement of the ‘590 Patent under 35 U.S.C. §§ … D. Tollefson and assigned to Lilly. The ‘590 Patent contains 16 claims. Claim 1 is the only independent…methods of treating ADHD. Notably, the ‘590 Patent claims do not and could not include tomoxetine. External link to document
2009-09-16 474 for Summary Judgment of Invalidity of U.S. Patent No. 5,658,590, Defendants’ Response to Eli Lilly and Cornpany… Surnmary Judgment of Invalidity of U.S. Patent No. 5,658,590, and Exhibits BBB, CCC and III that accompany…for Summary Judgment cf Invalidity of U.S. Patent No. 5,658,590, all of which were filed on July 27, 2009…for Summary Judgment of Invalidity cf U.S. Patent No. 5,658,590 and Defendants’ Response to Eli Lilly and…for Summary Judgment of Invalidity of U.S. Patent No. 5,658,590, along with Exhibits BBB, CCC and III that External link to document
2009-09-16 475 Response l. Lilly's U.S. Patent No. 5,658,590 ("'590 patent") is entitled "Treatment…hydrochloride. (See Pliszka, Ex. B, U.S. Patent No. 5,658,590(f1led Jan. ll, 1995).) Undisputed. …tomoxetine." (See Pliszka, Ex. B, '590 patent at claim l, col. 4, ll. 24-26.) Claims 2-16 depend…to respond. 4. The claims of the '590 patent cover the only FDA- approved use of Strattera® …Lilly submitted information concerning the '590 patent to the FDA in Undisputed. Page 2 of 22 External link to document
2009-12-31 494 Additionally, Defendants assert that U.S. Patent Nos. 4,018,895, 4,194,009, and 4,626,549 were not properly… prosecution of another patent (“the ‘985 Patent”). The ‘985 Patent pertains to a method of… the patent (i.e., to induce others to violate the patent by using atomextine in the patented manner… alleged infringement of U.S. Patent No. 5,658,590 (“the ‘590 Patent”). … known as atomoxetine. The ‘590 Patent is a method-of-use patent which claims methods of treating Attention External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
McKesson
Boehringer Ingelheim
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.